Want to see AU:PGC full AI Analyst Report?
PGC Stock Chart & Stats
AU$0.17
-AU$0.01(-2.04%)
At close: 4:00 PM EST
AU$0.17
-AU$0.01(-2.04%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.41
Previous CloseN/A
Volume365.08K
Average Volume (3M)501.29K
Market Cap
AU$240.02M
Enterprise ValueAU$722.97
Total Cash (Recent Filing)AU$30.86M
Total Debt (Recent Filing)AU$464.29M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,655,305,400
10 Day Avg. Volume605,379
30 Day Avg. Volume501,285
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)1.90
Price to Sales (P/S)0.17
P/FCF Ratio-26.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.17Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$3.74B
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Capital StructureModerate leverage (debt-to-equity ~0.93) and an equity ratio around 25.8% provide Paragon with financial flexibility to fund operations or targeted investments without excessive interest burden. A modest ROE (~6.45%) shows the business can generate returns while retaining capacity to absorb shocks and pursue measured growth initiatives over the medium term.
Service-led Distribution Business ModelParagon’s combination of medical equipment distribution with installation, maintenance, training and technical support creates recurring and aftermarket revenue streams. These services increase customer stickiness, raise switching costs and typically produce higher-margin, more stable cashflows over time versus pure product sales, supporting durable revenue mix resilience.
Operational Margin ImprovementReported modest gains in EBIT and EBITDA margins indicate management has found operational efficiencies or cost levers to improve profitability. If sustained as volumes stabilize, these margin improvements can materially enhance earnings quality and cash generation capacity, helping the company recover from prior profitability pressure over months.
Bears Say
Sharp Revenue ContractionA significant top-line decline (~22.5%) signals weakened demand or lost business in core hospital, laboratory and life-sciences channels. Persistent revenue contraction reduces scale benefits, limits ability to leverage fixed costs and constrains reinvestment, making it harder to restore margins and fund strategic initiatives without external support.
Very Thin Profitability MarginsLow gross margin (~9%) and near-breakeven net margin (~0.6%) reflect limited pricing power and slim profit capture from core sales. Such compressed margins leave little buffer for cost inflation or revenue volatility, restricting the firm's ability to self-fund growth and increasing sensitivity to operational setbacks over the medium term.
Negative Operating And Free Cash FlowNegative operating and free cash flow point to structural cash conversion issues and volatile cash generation. Continued cash outflows force reliance on external financing or asset sales to fund working capital and capex, which can constrain strategic flexibility and raise liquidity risk if adverse trends persist over the coming months.
Paragon Care Limited News
PGC FAQ
What was Paragon Care Limited’s price range in the past 12 months?
Paragon Care Limited lowest share price was AU$0.13 and its highest was AU$0.41 in the past 12 months.
What is Paragon Care Limited’s market cap?
Paragon Care Limited’s market cap is AU$240.02M.
When is Paragon Care Limited’s upcoming earnings report date?
Paragon Care Limited’s upcoming earnings report date is Aug 27, 2026 which is in 37 days.
How were Paragon Care Limited’s earnings last quarter?
Paragon Care Limited released its earnings results on Feb 24, 2026. The company reported -AU$1.29 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Paragon Care Limited overvalued?
According to Wall Street analysts Paragon Care Limited’s price is currently same.
Does Paragon Care Limited pay dividends?
Paragon Care Limited pays a Semiannually dividend of AU$0.006 which represents an annual dividend yield of N/A. See more information on Paragon Care Limited dividends here
What is Paragon Care Limited’s EPS estimate?
Paragon Care Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paragon Care Limited have?
Paragon Care Limited has 1,655,305,400 shares outstanding.
What happened to Paragon Care Limited’s price movement after its last earnings report?
Paragon Care Limited reported an EPS of -AU$1.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.195%.
Which hedge fund is a major shareholder of Paragon Care Limited?
Currently, no hedge funds are holding shares in AU:PGC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paragon Care Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.17 (0.00% )
AU$0.17 (0.00% )
Blogger Sentiment
Bullish
AU:PGC Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$27.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.09%
Trailing 12-Months
Company Description
Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, breast milk tracking, electrodes; sterilisable transducers designed for surgical procedures, digital theatre integration, infection control, infusion therapy, temperature management, enteral feeding, pain management, lasers, operating room products, surgical consumables, and ultrasound systems. In addition, the company offers aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; natural, traditional, and complementary health products and services; critical care and dental solutions; urology solutions, such as shockwave therapy, lasers, and accessories for infection control; medical products and consumables; and orthopaedics solutions, including hip and knee arthroplasty, upper and lower extremity, sports medicine, reverse shoulder replacement, and powered surgical tools. Further, it offers medical equipment repair, maintenance, and support services; technology and communication solutions, such as telephony, nurse call, access control, cctv, cordless, and Wi-Fi; supplies medical equipment to veterans, war widows, and families; and veterinary products. Additionally, it is involved in maintenance of technical medical equipment to the health, aged care, and veterinary markets; and distribution of pharmaceuticals, medical consumables, and complementary medicines to Australian healthcare market. The company is based in Mount Waverley, Australia.
PGC Stock 12 Month Forecast
Average Price Target
AU$0.17
▲(0.00% Upside)
Technical Analysis
Sigma Healthcare Ltd
―
Polynovo
―
Compumedics Limited
―
Epsilon Healthcare Limited
―
Trajan Group Holdings Ltd
―